We Claim:

1. A pharmaceutical composition comprising a combination of:

   a) Lactoferrin; and

   b) one or more Guanosine Nucleotide or a pharmaceutically acceptable salt thereof; wherein an amount of the Lactoferrin ranges from 5 to 90 % by wt. of the composition.

2. The pharmaceutical composition as claimed in claim 1, wherein the Guanosine Nucleotide is selected from Guanosine monophosphate (GMP), Guanosine diphosphate (GDP), Guanosine triphosphate (GTP) or a combination thereof.

3. The pharmaceutical composition as claimed in claim 1 or 2, wherein the pharmaceutically acceptable salt of the Guanosine Nucleotide is selected from a hydrochloride, a sulfate, a phosphate, an acetate, a lactate, a citrate, a pantothenate, an ascorbate, a succinate, a maleate, a fumarate, a gluconate, a magnesium salt, a potassium salt, a sodium salt, a zinc salt, a salt of diethanolamine and a combination thereof.

4. The pharmaceutical composition as claimed in any one of claims 1 to 3, wherein an amount of the Guanosine Nucleotide ranges from 1 to 75% by wt. of the composition.

5. The pharmaceutical composition as claimed in anyone of claims 1 to 4, wherein the composition further comprises elemental iron, vitamin C, vitamin A, folic acid, folate, vitamin B or a combination thereof.

6. The pharmaceutical composition as claimed in claim 5, wherein an amount of the elemental iron ranges from 30 to 45% by wt. of the composition.

7. The pharmaceutical composition as claimed in claim 5, wherein an amount of the vitamin C ranges from 5 to 65% by wt. of the composition.

8. The pharmaceutical composition as claimed in claim 5, wherein an amount of vitamin A ranges from 0.5 to 3% by wt. of the composition.

9. The pharmaceutical composition as claimed in claim 5, wherein an amount of folic acid or folate ranges from 0.05 to 0.75 % by wt. of the composition.

10. The pharmaceutical composition as claimed in claim 5, wherein an amount of the vitamin B ranges from 1 to 5% by wt. of the composition.

11. The pharmaceutical composition as claimed in any one of claims 1 to 10, further comprising a pharmaceutically acceptable excipients.

12. The pharmaceutical composition as claimed in claim 11, wherein the pharmaceutically acceptable excipients is selected from a diluent, a binder, a disintegrating agent, a lubricant, a glidant, a coating agent, a solvent or a combination thereof.

13. The pharmaceutical composition as claimed in claim 12, wherein an amount of

the diluent ranges from 5% to 45% by wt. of the composition,

the binder ranges from 1% to 7% by wt. of the composition,

the disintegrating agent ranges from 1% to 25% by wt. of the composition,

the lubricant ranges from 0.5% to 5% by wt. of the composition,

the glidant ranges from 0.5% to 5% by wt. of the composition,

the coating agent ranges from 1% to 15% by wt. of the composition, or

the solvent is quantity sufficient.

14. The pharmaceutical composition as claimed in any one of claims 1 to 13, wherein the composition is in a form selected from a tablet, a capsule, a pill, a hard capsule filled with liquid or solid, a soft capsule, a powder, a granule, a sachet, an enteric coated tablet or capsule, or a modified release tablet or capsule.

15. A process for preparation of a composition as claimed in any one of claims 1 to 14 comprising:

(a) individually weighing all the ingredients in separate containers;

(b) sifting previously weighed Lactoferrin, Guanosine Nucleotide or a pharmaceutically acceptable salt thereof, and optionally adding elemental iron, vitamin C, vitamin A, folic acid, folate or vitamin B, diluent and disintegrating agent separately;

(c) mixing contents of step (b);

(d) optionally, preparing a binder solution in a separate container and adding contents to step (c), and sieving the formed granulated wet mass to obtain granules;

(e) drying the obtained granulates until the level of dryness (LOD) is reduced to between 3.0 to 5.0 % w/w;

(f) sifting the semi-dried granules through a suitable sieve; and

(g) sifting previously weighed lubricant(s) and glidant(s) separately through a suitable sieve and adding contents to step (f) to obtain the composition.

16. Use of the pharmaceutical composition as claimed in any one of claims 1 to 14 for the manufacture of a medicament for the treatment of a condition selected from the group consisting of: Iron Deficiency Anaemia (IDA), Anaemia of Inflammation (AOI) and neuro-degenerative disorders related to iron homeostasis.